
ESMO 2019: New data from the TAILORx study on cohort with recurrence score 26-100 shows 93% cancer-free rate at 5 years
A new analysis from TAILORx, the largest ever breast cancer treatment trial, has been published…
A new analysis from TAILORx, the largest ever breast cancer treatment trial, has been published…